Males; n (%)
|
98(68)
|
Hemoglobin g/L, median (range)
|
88.0(43.0–166.0)
|
WBC (109/L), median (range)
|
21.88(3.01–117.57)
|
ANC (109/L), median (range)
|
7.07(0.30–66.91)
|
AMC (109/L), median (range)
|
3.58(1.02–57.72)
|
Platelets (109/L), median (range)
|
78(4–1001)
|
FAB subtypes, n (%)
| |
Myelodysplastic, MD
|
51(35)
|
Myeloproliferative, MP
|
94(65)
|
WHO subtypes, n (%)
| |
CMML-1
|
84(58)
|
CMML-2
|
61(42)
|
Mutational status
| |
ASXL1, n (%)
|
65(45)
|
SETBP1, n (%)
|
26(18)
|
TET2, n (%)
|
47(32)
|
SRSF2, n (%)
|
42(29)
|
aAcute leukemic transformation; n (%)
|
18(14)
|
aDeaths; n (%)
|
71(56)
|